eukaryotic initiation factor (eif)

Rocaglamide (Roc-A), isolated from the genus Aglaia, can be used to treat coughs, injuries, asthma, and inflammatory skin diseases. It is a potent inhibitor of NF-κB activation in T-cells.

GCN2-IN-1 (A-92) is an effective GCN2 inhibitor and can be utilized in cancer research as a chemotherapeutic agent.

GCN2-IN-6 is also a eIF2α kinase PERK inhibitor with an IC50 of 0.26 nM (in enzymatic assay) and 230 nM (in cells). GCN2-IN-6  is a potent, and orally available GCN2 inhibitor confirmed by in-house enzymatic (IC50 of 1.8 nM) and cellular assays (IC50 of 9

eIF4A3-IN-1 is a selective and potent inhibitor of eukaryotic initiation factor 4A3 (eIF4A3) with an IC50 value of 0.26 μM. eIF4A3-IN-1 inhibits cytosolic nonsense-mediated RNA decay at high concentrations.

GCN2iB is an ATP-competitive inhibitor of serine/threonine protein kinase, stress-responsive kinase (GCN2), with IC50 of 2.4 nM.

4E2RCat is an inhibitor of eIF4E-eIF4G interaction (IC50 = 13.5 μM) and effectively blocks coronavirus replication, as evidenced by reduced viral protein expression and decreased production of infectious virus.

4E1RCat is a dual inhibitor of eIF4E:eIF4 g and eIF4E:4E-BP1 interaction. And it inhibits the binding of eIF4 g to eIF4E with IC50 of 3.2 μM.

4EGI-1, a competitive eIF4E/eIF4 g interaction inhibitor, binds to eIF4E(KD=25 μM).

Briciclib (ON 014185) is a small molecule that inhibits cyclin D1 accumulation in Y cells.

SBI-0640756 (SBI-756) (SBI-756) is a first-in-class inhibitor that targets eIF4G1 and disrupts the eIF4F complex.

2BAct is a novel eif2b activator, preventing neurological defects caused by a chronic integrated stress response

Eukaryotic initiation factors (eIF) are proteins involved in the initiation phase of eukaryotic translation. Eukaryotic translation initiation factor 3 binds to the ribosome subunit-mRNA complex. It has been implicated in preventing the large ribosomal subunit from binding the small subunit before it is ready to commence elongation.